EP Patent

EP4525836A4 — Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms

Assigned to Hadasit Medical Research Services and Development Co · Expires 2026-02-25 · 0y expired

What this patent protects

Patent listed against Epidiolex.

Drugs covered by this patent

Patent Metadata

Patent number
EP4525836A4
Jurisdiction
EP
Classification
—
Expires
2026-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Hadasit Medical Research Services and Development Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.